Research situation of the third generation epidermal growth factor receptor inhibitor, osimertinib
10.13699/j.cnki.1001-6821.2017.14.024
- VernacularTitle:第3代表皮生长因子受体抑制药——奥西替尼研究状况
- Author:
Ping LI
1
;
Li WANG
;
Le-Chuan JIA
Author Information
1. 宁夏医科大学总医院肿瘤医院药剂科
- Keywords:
osimertinib;
non-small-cell-lung cancer;
acquired drug resistance
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(14):1371-1373
- CountryChina
- Language:Chinese
-
Abstract:
First-and second-generation epidermal growth factor recep tor (EGFR) tyrosine kinase inhibitors (TKIs) are the first or second-line treatment for metastatic non-small-cell-lung cancer (NSCLC) that harbor sensitizing EGFR mutations.However,acquired resistance to EGFR-KTIs monotherapy occurs invariably within 6 monthes to one year.In order to solve the acquired resistance of first-and second-generation EGFR-TKIs,in November 2015,the United States Food and Drug Administration (FDA) granted the approval of the tablet formulation of osimertinib for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC (as detected by an FDA-approved test)who have progressed on or after the first and second generation of EGFR-TKI therapy.In this review,we summarized the pharmacology,pharmacokinetics,clinical trials of osimertinib.
